Momelotinib improves outcomes in pretreated myelofibrosis
Last Updated: Wednesday, February 9, 2022
According to data from the randomized phase 3 MOMENTUM trial, the selective, orally bioavailable JAK1, JAK2 and ACVR1/ALK2 inhibitor momelotinib has demonstrated statistically significant benefit in total symptom score compared with danazol among patients with myelofibrosis previously treated with a JAK inhibitor. Twenty-five percent of patients in the momelotinib arm achieved total symptom score reduction of at least 50%, compared with 9% in the danazol arm (P = .0095).
Advertisement
News & Literature Highlights
